Thursday, March 17, 2011
FibroGen lands $40M milestone from Astellas
FibroGen Inc. received a $40 million milestone payment from Astellas Pharma Inc. as its investigational anemia therapy for chonic kidney disease patients advanced to Phase IIb studies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment